SecBot SecBot
S-4 ·Filed Aug 24, 2026

RGEN

REPLIGEN CORP
NEUTRAL
Impact 6/10
Horizonweeks Processed2mo ago SEC0001193125-26-363970
Notable filing: S-4
Actionable Insight • Neutral

Monitor the BioLife special meeting vote and HSR waiting period expiration (scheduled Sept 3, 2026). The fixed exchange ratio means RGEN's stock price movement directly impacts the deal's value for BLFS holders. Watch for any competing bids or regulatory delays that could alter the timeline or terms.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$181.69
T+0 close · Aug 24, 2026 · via day close
Latest settled
+1.56%
T+20 · $184.53 · next T+60 tomorrow
Vs SPY
+0.59%
α at T+20
Latest observation
+0.98%
T+56 · FF3 residual α
  1. T+0 · Aug 25 $181.69entry
  2. T+1 · 3mo ago −0.77%α −0.79% · $180.30
  3. T+5 · 3mo ago −6.42%α −5.88% · $170.02
  4. T+20 · 8w ago +1.56%α +0.59% · $184.53
  5. T+58 · todayOpen
  6. T+60 · tomorrow Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Repligen filed an S-4 registration statement for its acquisition of BioLife Solutions (BLFS). BioLife stockholders will receive $11.25 cash and 0.1442 Repligen shares per BLFS share, implying a value of ~$37.37 based on RGEN's August 21 close. The deal is expected to close in Q4 2026, subject to BioLife stockholder approval, HSR clearance, and other conditions. The fixed exchange ratio means the stock consideration value fluctuates with RGEN's price, creating uncertainty for BLFS holders voting on the deal.

Key Facts

  • Repligen is acquiring BioLife Solutions via a two-step merger for $11.25 cash + 0.1442 RGEN shares per BLFS share.
  • The implied value per BLFS share was ~$37.37 as of August 21, 2026, based on RGEN's $181.13 close.
  • BioLife stockholders must approve the merger; a special meeting is scheduled for [], 2026.
  • The deal is expected to close in Q4 2026, subject to HSR clearance and other conditions.
  • BioLife's financial advisor Centerview Partners opined the consideration is fair; BioLife will pay Centerview ~$25M total, with ~$24M contingent on closing.
  • If terminated under certain conditions, BioLife must pay Repligen a $59M termination fee.
  • The exchange ratio is fixed and will not adjust for market price changes, creating risk for BLFS holders.

Financial Impact

BioLife stockholders receive $11.25 cash + 0.1442 RGEN shares per BLFS share; implied value ~$37.37 as of Aug 21, 2026

acquisition considerationstock considerationcash consideration

Risk Factors

  • BioLife stockholders may not approve the merger, blocking the deal.
  • Regulatory approvals (HSR, foreign antitrust) could be delayed or impose conditions.
  • The fixed exchange ratio exposes BLFS holders to RGEN stock price declines before closing.
  • Integration risks could affect Repligen's post-merger financial performance.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-4 Filing (Primary)0001193125-26-363970
Document: 0001193125-26-363970-index.html0001193125-26-363970
Document: 0001193125-26-363970.txt0001193125-26-363970

Track record

16 reports on RGEN

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +31.47% at T+60 after the Jul 22, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 4/10 Entry $178.94 Now $162.78 −9.03% settles Feb 5
  2. Oct 30, 202617d ago 8-K Neutral 5/10 Entry $176.94 Now $162.78 −8.00% settles Jan 28
  3. Oct 27, 202620d ago 8-K Bullish 6/10 No price data
  4. Oct 27, 202620d ago Press Release Bullish 6/10 Entry $175.80 Now $162.78 −7.41% settles Jan 25
  5. Oct 15, 20264w ago Institutional Cluster Mixed 3/10 Entry $184.17 Now $162.78 −11.61% settles Jan 12
  6. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $167.22 Now $162.78 −2.66% settles Jan 4
  7. Oct 6, 20265w ago 8-K Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
  8. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $174.86 Now $162.78 −6.91% settles Dec 31
  9. Aug 24, 202611w ago S-4 Neutral 6/10 Viewing Entry $181.69 Now $162.78 −10.41% settles Nov 18
  10. Jul 28, 202615w ago 8-K Bullish 7/10 Entry $145.34 to $180.01 Now $162.78 +12.00% ▲ +23.85% +19.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (14h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 25, 2026